Drugs / PRI-002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06182085 | Feb 2024 → Apr 2026 | Alzheimer disease | PRInnovation GmbH | Completed | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-03-17 | Priavoid | Priavoid Presents Initial Phase 2 Data Suggesting Favorable Safety Profile for Alzheimer’s Candidate PRI-002 at AD/PD™ 2026 priavoid.com ↗ |
| 2025-02-26 | Priavoid | PRImus-AD: Recruitment for Phase II clinical trial of Alzheimer’s drug PRI-002 successfully completed priavoid.com ↗ |
| 2023-11-20 | Priavoid | New Alzheimer’s drug PRI-002 receives EMA approval for Phase II study priavoid.com ↗ |
| 2021-02-04 | Priavoid | Alzheimer´s Research: Important Milestone for PRI-002 priavoid.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRI-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06182085 ↗ |
| Modality | Peptide | “PRI-002 is an all D-amino acid peptide (all-D-peptide)” NCT06182085 ↗ |
| Route | Oral | “Oral administration” NCT06182085 ↗ |